Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Medical Devices

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Comment by elgin1on May 26, 2020 3:05pm

90 Views

Post# 31074448

RE:RE:RE:RE:RE:RE:Sanofi-paragraph 3 "end it's hunt..." ???

Offering can be higher or lower . Look at Gbr . They did a flow through offering at a much higher price than their share price. So you are correct as long as the offering is open to the public and not only insiders. If you do a pp significantly lower than sp you will pi$$ off shareholders but in order to raise money and get larger position in equity, institutional investors will do a pp.

I am not sayin that a pp is in the works . I always question Biotecks motive. But technically you are right . Normally a pp is close to the sp or slightly less to entice potential investors . But if it is sought after equity, it can the other way . Good point I stand corrected.

Bullboard Posts

Critical materials crisis: Diversifying away from China’s monopoly